Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer.

Breyer BN, Whitson JM, Carroll PR, Konety BR.

Urol Oncol. 2010 Sep-Oct;28(5):510-4. doi: 10.1016/j.urolonc.2008.11.019. Epub 2009 Jan 26.

2.

Intravesical gemcitabine for non-muscle invasive bladder cancer.

Jones G, Cleves A, Wilt TJ, Mason M, Kynaston HG, Shelley M.

Cochrane Database Syst Rev. 2012 Jan 18;1:CD009294. doi: 10.1002/14651858.CD009294.pub2. Review.

PMID:
22259002
3.

Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.

Shelley MD, Jones G, Cleves A, Wilt TJ, Mason MD, Kynaston HG.

BJU Int. 2012 Feb;109(4):496-505. doi: 10.1111/j.1464-410X.2011.10880.x. Review.

4.

Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer.

Shelley MD, Court JB, Kynaston H, Wilt TJ, Coles B, Mason M.

Cochrane Database Syst Rev. 2003;(3):CD003231. Review. Update in: Cochrane Database Syst Rev. 2015;11:CD003231.

PMID:
12917955
5.

Intravesical chemotherapy plus bacille Calmette-Guérin in non-muscle invasive bladder cancer: a systematic review with meta-analysis.

Houghton BB, Chalasani V, Hayne D, Grimison P, Brown CS, Patel MI, Davis ID, Stockler MR.

BJU Int. 2013 May;111(6):977-83. doi: 10.1111/j.1464-410X.2012.11390.x. Epub 2012 Dec 17. Review.

6.

Experience with Sequential Intravesical Gemcitabine and Docetaxel as Salvage Therapy for Non-Muscle Invasive Bladder Cancer.

Velaer KN, Steinberg RL, Thomas LJ, O'Donnell MA, Nepple KG.

Curr Urol Rep. 2016 May;17(5):38. doi: 10.1007/s11934-016-0594-2. Review.

PMID:
26968418
7.

Update on intravesical agents for non-muscle-invasive bladder cancer.

Shariat SF, Chade DC, Karakiewicz PI, Scherr DS, Dalbagni G.

Immunotherapy. 2010 May;2(3):381-92. doi: 10.2217/imt.10.1. Review. Erratum in: Immunotherapy. 2014;6(11):1238.

8.

The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review.

Lammers RJ, Witjes JA, Inman BA, Leibovitch I, Laufer M, Nativ O, Colombo R.

Eur Urol. 2011 Jul;60(1):81-93. doi: 10.1016/j.eururo.2011.04.023. Epub 2011 Apr 20. Review.

PMID:
21531502
9.

A systematic overview of chemotherapy effects in urothelial bladder cancer.

Nilsson S, Ragnhammar P, Glimelius B, Nygren P; SBU-group. Swedish Council of Technology Assessment in Health Care.

Acta Oncol. 2001;40(2-3):371-90. Review.

PMID:
11441942
10.

Actual experience and future development of gemcitabine in superficial bladder cancer.

Gontero P, Frea B.

Ann Oncol. 2006 May;17 Suppl 5:v123-8. Review.

PMID:
16807439
11.

Gemcitabine in bladder cancer.

El Karak F, Flechon A.

Expert Opin Pharmacother. 2007 Dec;8(18):3251-6. Review.

PMID:
18035967
12.

Optimizing intravesical mitomycin C therapy in non-muscle-invasive bladder cancer.

Zargar H, Aning J, Ischia J, So A, Black P.

Nat Rev Urol. 2014 Apr;11(4):220-30. doi: 10.1038/nrurol.2014.52. Epub 2014 Mar 11. Review.

PMID:
24619373
13.

Treatment options in non-muscle-invasive bladder cancer after BCG failure.

Brooks NA, O'Donnell MA.

Indian J Urol. 2015 Oct-Dec;31(4):312-9. doi: 10.4103/0970-1591.166475. Review.

14.

Gemcitabine-containing regimens in bladder cancer: A new standard of care.

von der Maase H.

Semin Oncol. 2001 Jun;28(3 Suppl 10):1-3. Review. No abstract available.

PMID:
11510026

Supplemental Content

Support Center